Lipitor's Post-Patent Sales Decline
Lipitor (atorvastatin), Pfizer's blockbuster statin, peaked at $12.9 billion in US sales in 2010. After generic entry in November 2011 following patent expiry, brand sales dropped 85% to $1.9 billion globally by 2013, then to under $300 million by 2015 as generics captured 90%+ market share.[1][2]
How Competitors' Post-Patent Blockbusters Fared
Other statin competitors and similar cholesterol drugs saw comparable sharp declines when generics launched, typically losing 80-95% of brand sales within 1-2 years:
- Crestor (rosuvastatin, AstraZeneca): Peaked at $5.3 billion globally in 2013. US patent expired March 2016; brand sales fell to $1.2 billion by 2017 (77% drop), generics took 92% share.[1][3]
- Zocor (simvastatin, Merck): $4.4 billion peak in 2003. Patent expiry June 2006 led to 90% US sales plunge to $400 million by 2008.[2]
- Pravachol (pravastatin, Bristol-Myers Squibb): Peaked ~$1 billion in early 2000s. Post-2006 expiry, sales halved annually, near zero by 2010.[1]
Non-statin comparables like Nexium (esomeprazole, AstraZeneca) dropped 85% post-2014 expiry, from $6.3 billion to under $1 billion.[2]
| Drug | Peak Year Sales (Global) | Patent Expiry | Sales 2 Years Post-Expiry (% Drop) | Generic Penetration |
|------|---------------------------|---------------|------------------------------------|---------------------|
| Lipitor | $13B (2010) | 2011 | $2B (85%) | 95%+ |
| Crestor | $5.3B (2013) | 2016 | $1.2B (77%) | 92% |
| Zocor | $4.4B (2003) | 2006 | $0.4B (91%) | 90%+ |
| Nexium | $6.3B (2013) | 2014 | $0.9B (86%) | 88% |
Factors Driving Similar Patterns
Generics enter at 80-90% lower prices, eroding brand loyalty via pharmacy substitution laws. US statin market shrank from $20B pre-2011 to $3B by 2018 as volumes shifted.[3] Exceptions like evergreening delays (e.g., Crestor via pediatric extensions) slow but don't prevent 80%+ drops.[1]
Ongoing Revenue from Authorized Generics and Legacy
Pfizer earned $200-300 million annually from Lipitor authorized generics post-2011. Crestor follows suit, with AstraZeneca reporting $100 million+ in 2018 from branded generics.[2]
[1]: DrugPatentWatch.com - Lipitor Patents
[2]: IQVIA Institute Reports on Generic Impact (2015-2020)
[3]: FDA Orange Book and AstraZeneca Annual Reports